Celgene $8.0 Billion Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Celgene Corporation of $8.0 billion aggregate principal amount of notes. The notes were issued in…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common shares of Cynapsus Therapeutics Inc., including 675,000 common…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…
Laboratory Corporation of America Holdings $2.9 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on a public offering by Laboratory Corporation of America Holdings (LabCorp) of $500 million…